Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Blood cancer journal·2026
Same author

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Blood cancer journal·2026
Same author

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.

Blood advances·2025
Same author

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.

Blood cancer journal·2025
Same author

The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study.

Haematologica·2025
Same author

Editor's Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Cancer research·2025
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
Same journal

Precision Transfusion Medicine in the Omics Era.

Blood·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

RARα2 expression confers myeloma stem cell features.

Ye Yang1, Jumei Shi, Giulia Tolomelli

  • 1Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

Blood
|July 13, 2013
PubMed
Summary
This summary is machine-generated.

Increased RARα2 expression promotes multiple myeloma stem cell features, leading to drug resistance and poor prognosis. Targeting RARα2 or its downstream pathways may offer a new strategy to eliminate these resistant myeloma stem cells.

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: May 9, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Stem Cells

Background:

  • Retinoic acid receptor alpha 2 (RARα2) expression is elevated in relapsed multiple myeloma (MM) and associated with poor prognosis in newly diagnosed patients.
  • RARα2's role in multiple myeloma stem cell (MMSC) biology and drug resistance is not fully understood.

Purpose of the Study:

  • To investigate the role of RARα2 in conferring multiple myeloma stem cell characteristics.
  • To elucidate the mechanisms by which RARα2 induces drug resistance.
  • To evaluate therapeutic strategies targeting RARα2 and its associated pathways in preclinical models.

Main Methods:

  • Assessed RARα2 expression in MMSC fractions.
  • Overexpressed and knocked down RARα2 in MM cell lines to evaluate functional consequences.
  • Analyzed activation of Wnt and Hedgehog (Hh) signaling pathways.
  • Measured drug resistance, side population, aldehyde dehydrogenase activity, and embryonic stem cell gene expression.
  • Utilized the 5TGM1 mouse model to test therapeutic interventions targeting Wnt/Hh pathways.

Main Results:

  • Higher RARα2 expression was found in the MMSC fraction.
  • RARα2 overexpression increased drug resistance, clonogenic potential, side population, and aldehyde dehydrogenase levels, while activating Wnt/Hh pathways and upregulating embryonic stem cell genes.
  • RARα2 induced drug resistance via ABCC3 and Bcl-2 family members; Wnt signaling or ABCC3 inhibition overcame this resistance.
  • In vivo, targeting Wnt/Hh pathways reduced tumor burden and improved survival in the 5TGM1 mouse model.

Conclusions:

  • Increased RARα2 expression drives multiple myeloma stem cell properties, including drug resistance and pathway activation.
  • Targeting RARα2 or its downstream Wnt and Hh signaling pathways presents a promising therapeutic strategy for eliminating MMCs and overcoming treatment resistance.